Willow Biosciences (TSX: WLLW) (OTCQX: CANSF)
, a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, will exercise its right under the terms of an Oct. 29, 2020, warrant indenture to accelerate the expiry date of common share purchase warrants issued that same day. The warrant indenture stipulates that the company may accelerate the expiry of the 2020 warrants if the volume weighted average trading price of the company’s common shares on the Toronto Stock Exchange surpasses $1.20 for at least 20 consecutive trading days, which occurred at the close of markets on Jan. 22, 2021. In order to do so, Willow Biosciences must deliver written notice to the holders of the 2020 warrants within 10 business days of the acceleration trigger; the company will deliver those notices on Jan. 26, 2021, which will have been deemed to be delivered by Jan. 29, 2021. Unless exercised, the 2020 warrants are now scheduled to expire on Feb. 28, 2021, and any 2020 warrants that have not been exercised by 5 p.m. (Calgary time) on that date will be cancelled. Warrantholders may exercise warrants in their name by following the instructions on the exercise notice form attached to the certificate evidencing the 2020 warrants.
To view the full press release, visit https://ibn.fm/vLb7f
About Willow Biosciences Inc.
Willow is a Canadian biotechnology company based in Vancouver, British Columbia, which produces high-purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow’s current focus is on the production of cannabinoids for the treatment for pain, anxiety, obesity and brain disorders, among other significant indications. Willow’s science team has a proven track record of developing manufacturing technologies for high-purity compounds in pain and cancer treatments. Willow’s manufacturing process creates a consistent, scalable and sustainable product that allows for the discovery and development of new life-changing drugs. For more information about the company, visit www.WillowBio.com
NOTE TO INVESTORS:
The latest news and updates relating to WLLW are available in the company’s newsroom at http://ibn.fm/WLLW
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.